Formycon and MS Pharma Collaborate for Keytruda® Biosimilar in MENA

Formycon AG and MS Pharma have inked an exclusive agreement to commercialize the Keytruda® biosimilar candidate, FYB206, in the Middle East and North Africa (MENA) region. This agreement marks a significant step for Formycon's cancer therapy candidate, building on previous successful collaborations with MS Pharma. The deal includes an option for a future technology transfer, aiming to leverage both companies' strengths in biosimilar production and distribution.

FYB206 is nearing the end of its clinical development phase, with primary endpoint results expected in early 2026. The agreement grants Formycon an upfront payment and potential milestone-based financial incentives. The MENA market, where Keytruda® has robust sales, highlights a strong demand for oncology treatments. Both companies aim to enhance access to this crucial biosimilar, bolstered by MS Pharma's manufacturing capabilities in Saudi Arabia.